Conclusion

The PARAGEN collection represents a significant advance in the strategic exploitation of bacteriocins, opening up innovative avenues to meet the challenges of the "One Health" approach. Research devoted to these peptides in the treatment of bacterial infections reveals considerable therapeutic potential, underlined by their ability to precisely target pathogens, while preserving the beneficial microbiome. What's more, the promising alliance between synthetic biology and artificial intelligence marks the threshold of an imminent revolution in the discovery and optimization of new bacteriocins, accelerating their application and integration in various sectors. Despite existing challenges, the outlook for bacteriocins is exceptionally promising, carrying with it as yet untapped potential.